P.2.b.018 Impaired face emotion recognition in depression: the influence of pharmacological and psychological factors

groups versus placebo with 11/15 (73.3%) responders in 2X/wk group versus 2/14 (14.3%) in placebo [p = 0.008]; 7/17 (41.2%) responders in 3X/wk group versus 3/16 (18.8%) in placebo [p = 0.160]. During DB phase, more ketamine-treated patients had >1 treatment emergent adverse event (TEAE) compared with placebo-treated patients. Incidence of TEAEs was similar between ketamine-treated groups [2×/wk: 15 (83%); 3×/wk: 13 (77%)] with headache, anxiety, dissociation, nausea, and dizziness as the most common ( 20% of patients) TEAEs observed primarily during and shortly after the infusion. No death was reported. Conclusion: Ketamine (0.5mg/kg IV) at both dose frequencies (2X/wk and 3X/wk) was similarly efficacious suggesting that ketamine dose regimens may be further optimized for safety and convenience. Both dose frequencies demonstrated statistically significant and clinically meaningful changes in MADRS total score from baseline to day 15 and showed improvement in depression symptoms in TRD patients within the first week in QIDS-SR14 with the 2×/wk dose frequency achieving statistical significance on day 2. No new safety findings emerged.